Codexis Inc's Corporate Customers have recorded an increase in their cost of revenue by 11.27 % in the 2 quarter 2026 year on year, sequentially costs of revenue grew by 1.18 %. During the corresponding time, Codexis Inc saw a revenue deteriorated by -2.69 % year on year, sequentially revenue fell by -2.18 %. While revenue at the Codexis Inc 's corporate clients recorded rose by 5.99 % year on year, sequentially revenue grew by 3.89 %.
Codexis Inc's Customers have recorded an increase in their cost of revenue by 11.27 % in the 2 quarter 2026 year on year, sequentially costs of revenue grew by 1.18 %, for the same period Codexis Inc revnue deteriorated by -2.69 % year on year, sequentially revenue fell by -2.18 %.
Codexis Inc's Comment on Sales, Marketing and Customers
The company provides siRNA constructs for pre-clinical testing and clinical-stage manufacturing and testing. In 2025, it produced non-GMP-grade siRNA drug substances for customers through its Innovation Lab under development services contracts. The company has partnerships with three large-scale contract development and manufacturing organizations (CDMOs) to evaluate its ECO platform for synthesizing GMP-grade siRNA drug substances. These partnerships are currently in feasibility testing, with plans to advance at least one in 2026. Customers benefit from access to large-scale commercial manufacturers familiar with the company's processes, facilitating manufacturing scale-up. In its small molecule pharmaceutical biocatalysis business, the company utilizes its CodeEvolver technology platform to develop optimized enzymes used by several major pharmaceutical companies to enhance manufacturing efficiency and productivity of small molecule therapeutics.
In a noteworthy development that emphasizes Codexis, Inc. s strategic expansion and robust performance in the competitive biopharmaceutical landscape, the company announced on November 10, 2025, the signing of a lease for a state-of-the-art 34,000 square foot Good Manufacturing Practices (GMP) manufacturing facility in Hayward, California. This strategic investment signals Codexis’s commitment to enhancing its production capabilities, particularly as demand amplifies for its enzymatic solutions crucial in the manufacturing of complex therapeutics.The company s growth narrative is underpinned by impressive financial results. Codexis Inc. reported a staggering revenue increase of 92.1% year over year, and an...
Codexis, Inc. has recently finalized an asset purchase agreement with Crosswalk Therapeutics, a significant milestone in the field of gene therapy. This leading enzyme engineering company has acquired Crosswalk Therapeutics investigational compounds for Fabry and Pompe diseases. The deal includes future development and commercial milestone payments, as well as a low-to-mid single-digit percentage net sales-based royalty.In the first quarter, Codexis Inc s corporate clients experienced a concerning -18.42% deterioration in their costs of revenue compared to the previous year. However, sequentially, there was a growth of 38.6% in costs of revenue. During the same period, Codexis Inc recorded a remarkable incr...
Codexis Inc’s Comment on Sales, Marketing and Customers
The company provides siRNA constructs for pre-clinical testing and clinical-stage manufacturing and testing. In 2025, it produced non-GMP-grade siRNA drug substances for customers through its Innovation Lab under development services contracts. The company has partnerships with three large-scale contract development and manufacturing organizations (CDMOs) to evaluate its ECO platform for synthesizing GMP-grade siRNA drug substances. These partnerships are currently in feasibility testing, with plans to advance at least one in 2026. Customers benefit from access to large-scale commercial manufacturers familiar with the company's processes, facilitating manufacturing scale-up. In its small molecule pharmaceutical biocatalysis business, the company utilizes its CodeEvolver technology platform to develop optimized enzymes used by several major pharmaceutical companies to enhance manufacturing efficiency and productivity of small molecule therapeutics.
Sources:
Codexis inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Codexis inc’s corporate clients.
For your research, we’ve provided 9 tables on Codexis inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
136.84 %
5.99 %